Unitedhealth Group Inc

2026 results + 2027 confidence; guidance tightened - Q3’26: Revenue ~$113B; Adjusted EPS $4.69 (vs $2.92 a year ago); Consolidated medical care ratio 88.4% (vs 89.9%). - The company reaffirmed an “adjusted EPS at least $20.50” for full-year 2026, with the updated view reflecting Q3 performance plus expected end-of-year investment. - Management reiterated confidence to sustain 13%–16% long-term growth and suggested current analyst consensus for 2027 may understate opportunity; they framed the lower end of the range as a “more reasonable starting point.”

AI + modernization driving operating improvements (including prior authorization reforms) - AI adoption: AI chart summarization for >40% of employed clinicians, cutting chart review time by 33%; appeal cycle times down 26% (expected to accelerate in 2027). - Medicare AEP 2026 reform: AI-powered plan recommendation using care history + local plan options. - Prior authorization overhaul expected to be fully implemented: reducing total prior authorizations by 30%, including a two-thirds reduction for members under age 18—positioned as early evidence of simplifying processes for better clinician/patient experience.

Medicare Advantage: strong access + quality focus; margin outlook improving - Access and product positioning: >94% of eligible seniors have access to a UnitedHealthcare Medicare plan; ~90% have access to a plan with a $0 premium option. - Product mix emphasis for 2027: High-value HMO, C-SNP, D-SNP, and chronic special needs (chronic special needs coverage targeted for nearly 50M eligible individuals). - Stars/quality: initial Star ratings for payment year 2028 reflect investment; expectation to approach ~75% of members in 4+ Star plans vs industry ~70%. - Margin (most investor-relevant update): Medicare Advantage margins now expected near the top end of a stated 2%–4% range for 2026 (attributed to cost management, durable product actions, and quality/AI/modernization investments).